Relapse after orthodontic treatment is shown to be a recurring problem. Against this, the orthodontist has presented a limited arsenal of measures that would prevent the regression of the goals achieved. The use of drugs that inhibit osteoclastic bone activity inherent to all tooth movement may be an alternative to avoid the use of more containment methods. In the present study, the efficacy of zoledronate and osteoprotegerin (OPG-Fc) as pharmacological relapse agents was determined after conducting a dental movement in a model of rats. Such treatment was conducted for 21 days in three groups that had been treated with OPG-Fc, zoledronate and a vehicle of phosphate-buffered saline to be monitored after another 21 days of the relapse that occurred in them. The groups treated with both biological inhibitors were effective when preventing relapse compared to the control group, also showing a similar behavior when bone volume fraction before and after treatment and after relapse phase was measured. Our results indicate that both OPG-Fc and zoledronate inhibit osteoclast activity efficiently when this involves preventing dental relapse, which could have a clear clinical utility in preventing unwanted tooth movement.
(Rev Esp Ortod. 2016;46(1):021-028)